Advanced search
Publication Cover
Future Cardiology Volume 2, 2006 - Issue 3
Submit an article Journal homepage
226
Views
1
CrossRef citations to date
0
Altmetric
Review

Antiplatelet Therapy: Current Strategies and Future Trends

Udaya S Tantrya Sinai Center for Thrombosis ResearchHoffberger BuildingSuite 56 2401 W. Belvedere AveBaltimoreMD21215USA Tel.: +1 410 601 9600; Fax: +1 410 601 9601; [email protected]
,
Amena Etheringtonb Sinai Center for Thrombosis ResearchHoffberger BuildingSuite 56 2401 W. Belvedere AveBaltimoreMD21215USA. Tel.: +1 410 601 9600; Fax: +1 410 601 9601; [email protected]
,
Kevin P Blidenc Sinai Center for Thrombosis ResearchHoffberger BuildingSuite 56 2401 W. Belvedere AveBaltimoreMD21215USA. Tel.: +1 410 601 9600; Fax: +1 410 601 9601; [email protected]
&
Paul A Gurbeld Sinai Center for Thrombosis ResearchHoffberger BuildingSuite 56 2401 W. Belvedere AveBaltimoreMD21215USA. Tel.: +1 410 601 9600; Fax: +1 410 601 9601; [email protected]
Pages 343-366 | Published online: 09 May 2006

Bibliography

  • Gurbel PA , BlidenKP, HayesKM, Tantry U: Platelet activation in myocardial ischemic syndromes. Expert Rev. Cardiovasc. Ther., 2(4), 535–545 (2004).
  • Tantry US , BlidenKP, GurbelPA: Resistance to antiplatelet drugs: current status and future research.Expert Opin. Pharmacother., 6, 2027–2045 (2005).
  • Strukova S : Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis.Front. Biosci., 11, 59–80 (2006).
  • Ruggeri ZM : Platelets in atherothrombosis.Nat. Med., 8, 1227–1234 (2002).
  • Furie B , FurieBC: Thrombus formation in vivo.J. Clin. Invest., 115, 3355–3362 (2005).
  • Jackson SP , NesbittWS, KulkarniS: Signaling events underlying thrombus formation.J. Thromb. Haemost., 1, 1602–1612 (2003).
  • Dorsam RT , TulucM, KunapuliSP: Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets.J. Thromb. Haemost., 2, 804–812 (2004).
  • Gawaz M : Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium.Cardiovasc. Res., 61, 498–511 (2004).
  • Samara WM , GurbelPA: The role of platelet receptors and adhesion molecules in coronary artery disease.Coron. Artery Dis., 14, 65–79 (2003).
  • van der Meijden PE , FeijgeMA, GiesenPLet al.: Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb. Haemost., 93, 1128–1136 (2005).
  • Tan KT , LipGY: The potential role of platelet microparticles in atherosclerosis.Thromb. Haemost., 94, 488–492 (2005).
  • Gurbel PA , KereiakesDJ, DalesandroMRet al.: Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. Am. Heart J., 139, 320–328 (2000).
  • Matsagas MI , GeroulakosG, Mikhailidis DP: The role of platelets in peripheral arterial disease: therapeutic implications. Ann. Vasc. Surg., 16, 246–258 (2002).
  • Gurbel PA , BlidenKP, SamaraWet al.: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol., 46, 1827–1832 (2005).
  • Matetzky S , ShenkmanB, GuettaVet al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109, 3171–3175 (2004).
  • Ajzenberg N , AubryP, HuisseMGet al.: Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J. Am. Coll. Cardiol., 45, 1753–1756 (2005).
  • Vishnupriya K , FisshaM, BlidenKPet al.: Increased risk in patients with high platelet aggregation on chronic clopidogrel therapy undergoing repeat PCI; is the current anti-platelet coverage adequate? J. Am. Coll. Cardiol., 47, 45B (2006).
  • Gurbel PA , ZamanK, BlidenKP, Tantry US: Maximum clot strength is a novel and highly predictive indicator of restenosis: a potential future measure to determine who needs antiproliferative therapy and how much. J. Am. Coll. Cardiol., 47, 43B (2006).
  • Gurbel PA , BlidenKP, ZamanKAet al.: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of PLATELETS (CLEAR PLATELETS) study. Circulation, 111, 1153–1159 (2005).
  • Gurbel PA , BlidenKP, TantryUS: The effect of clopidogrel with and without eptifibatide on tumor necrosis factor-a and C-reactive protein release after elective stenting: Results of the CLEAR PLATELETS-Ib study.J. Am. Coll. Cardiol. (2006) (In Press).
  • Gurbel PA , BlidenKP, GuyerKet al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol., 46, 1820–1826 (2005).
  • Cuisset T , FrereC, QuiliciJet al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost., 4(3), 542–549 (2006).
  • Watala C : Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus.Curr. Pharm. Des., 11, 2331–2365 (2005).
  • Preston RA , JyW, JimenezJJet al.: Effects of severe hypertension on endothelial and platelet microparticles.Hypertension, 41, 211–217 (2003).
  • Sener A , OzsavciD, ObaRet al.: Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia? Clin. Biochem., 38, 1081–1087 (2005).
  • Patrono C , CollerB, DalenJEet al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest, 119(Suppl. 1), S39–S63 (2001).
  • Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 324, 71–86 (2002).
  • CAPRIE Streering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 348, 1329–1339 (1996).
  • Yusuf S , ZhaoF, MehtaSRet al.: Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 345, 494–502 (2001).
  • Steinhubl SR , BergerPB, MannJTet al. 3rd : CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288, 2411–2420 (2002).
  • Sakariassen KS , TurittoVT, Baumgartner HR: Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J. Thromb. Haemost., 2, 1681–1690 (2004).
  • Bossavy JP , CadroyY, SakariassenKet al.: Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model. Ann. Vasc. Surg., 13, 393–401 (1999).
  • Bossavy JP , ThalamasC, SagnardLet al.: A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood, 92, 1518–1525 (1998).
  • Orvim U , BarstadRM, VlasukGPet al.: Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler. Thromb. Vasc. Biol., 15, 2188–2194 (1995).
  • Vane JR : Inhibition of prostaglandin syntheses as a mechanism of action of for aspirin-like drugs.Nat. New. Biol., 231, 232–235 (1971).
  • Roth GJ , StanfordN, MajerusPW: Acetylation of prostaglandin synthase by aspirin.Proc. Natl Acad. Sci. USA, 72, 3073–3077 (1975).
  • Loll PJ , PicotD, GaravitoRM: The structural basis of aspirin activity inferred fron the crystal structure of inactivated prostaglanding H2 synthase.Nat. Struct. Biol., 2, 637–643 (1995).
  • Leon MB , BaimDS, PopmaJJet al.: Clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med., 339, 1665–1671 (1998).
  • Gavaghan TP , GebeskiV, GavaghanTP, GebskiV, BaronDW: Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study.Circulation, 83, 1526–1533 (1991).
  • Goldman S , CopelandJ, MoritzTet al.: Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation, 77, 1324–1332 (1988).
  • Stein PD , SchunemannHJ, DalenJE, GuttermanD: Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126(Suppl. 3), S600–S608 (2004).
  • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2, 349–360 (1988).
  • Roux S , ChristellerS, LudinE: Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis.J. Am. Coll. Cardiol., 19, 671–677 (1992).
  • Awtry EH , LoscalzoJ: Aspirin.Circulation, 101, 1206–1218 (2000).
  • Lauer MS : Clinical practice. Aspirin for primary prevention of coronary events.N. Engl. J. Med., 346, 1468–1474 (2002).
  • Tendera M , WojakowskiW: Role of antiplatelet drugs in the prevention of cardiovascular events.Thromb. Res., 110, 355–359 (2003).
  • Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet, 351, 233–241 (1998).
  • Hansson L , ZanchettiA, CarruthersSGet al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351, 1755–1762 (1998).
  • Eidelman RS , HebertPR, WeismanSM, HennekensCH: An update on aspirin in the primary prevention of cardiovascular disease.Arch. Intern. Med., 163, 2006–2010 (2003).
  • Williams A , HennekensCH: The role of aspirin in cardiovascular diseases – forgotten benefits?Expert Opin Pharmacother., 5, 109–115 (2004).
  • Chen ZM , SandercockP, PanHCet al.: Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke, 31, 1240–1249 (2000).
  • Ridker PM , CushmanM, StampferMJet al.: Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N. Engl. J. Med., 336, 973–979 (1997).
  • Nurses Manson JE , StampferMJet al., Colditz GA : A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA, 266, 521–527 (1991).
  • Ridker PM , CookNR, LeeIMet al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 352, 1293–1304 (2005).
  • Levin RI : The puzzle of aspirin and sex.N. Engl. J. Med., 352, 1366–1368 (2005).
  • Berger JS , RoncaglioniMC, AvanziniFet al.: Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA, 295, 306–313 (2006).
  • Meune C , MaheI, SolalACet al.: Comparative effect of aspirin and clopidogrel on arterial function in CHF. Int. J. Cardiol., 106, 61–66 (2006).
  • Massie BM : Aspirin use in chronic heart failure: what should we recommend to the practitioner?J. Am. Coll. Cardiol., 46, 963–966 (2005).
  • Hennekens CH : Update on aspirin in the treatment and prevention of cardiovascular disease.Am. J. Manag. Care, 8(Suppl. 22), S691–S700 (2002).
  • Patrono C : Aspirin resistance: definition, mechanisms and clinical read-outs.J. Thromb. Haemost., 1, 1710–1713 (2003).
  • Michelson AD , CattaneoMet al., Eikelboom JW : Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost., 3, 1309–1311 (2005).
  • Tantry US , BlidenKP, GurbelPA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.J. Am. Coll. Cardiol., 46, 1705–1709 (2005).
  • Schwartz KA , SchwartzDE, GhoshehKet al.: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol., 95, 973–975 (2005).
  • Abaci A , YilmazY, CaliskanMet al.: Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb. Res., 116, 465–470 (2005).
  • Gonzalez-Conejero R , RiveraJ, CorralJ, AcunaC, GuerreroJA, VicenteV: Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?Stroke, 36, 276–280 (2005).
  • Maree AO , CurtinRJ, DooleyMet al.: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J. Am. Coll. Cardiol., 46, 1258–1263 (2005).
  • Gachet C : Regulation of platelet functions by P2Y receptors.Ann. Rev. Pharmacol. Toxicol., 46, 277–300 (2006).
  • Lau WC , GurbelPA, WatkinsPBet al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 109, 166–171 (2004).
  • Savi P , CombalbertJ, GaichCet al.: The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb. Haemost., 72, 313–317 (1994).
  • Hermann A , RauchBH, BraunM, Schror K, Weber AA: Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets, 12, 74–82 (2001).
  • Xiao Z , TherouxP: Clopidogrel inhibits platelet–leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.J. Am. Coll. Cardiol., 43, 1982–1988 (2004).
  • Di Nisio M , BijsterveldNR, MeijersJCet al.: Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 46, 1582–1583 (2005).
  • Evangelista V , ManariniS, Dell’ElbaGet al.: Clopidogrel inhibits platelet–leukocyte adhesion and platelet-dependent leukocyte activation. Thromb. Haemost., 94, 568–577 (2005).
  • Gurbel PA , BlidenKP, GuyerK, Aggarwal N, Tantry US: Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. J. Am. Coll. Cardiol., 47, 17B (2006).
  • Cannon CP , CAPRIE Investigators: Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am. J. Cardiol., 90, 760–762 (2002).
  • Cadroy Y , BossavyJP, ThalamasC, Sagnard L, Sakariassen K, Boneu B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation, 101, 2823–2828 (2000).
  • Yusuf S , ZhaoF, MehtaSRet al.: Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 345, 494–502 (2001).
  • Mehta SR , YusufS, PetersRJet al.: Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358, 527–533 (2001).
  • Steinhubl SR , BergerPB, MannJTet al. 3rd : CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288, 2411–2420 (2002).
  • Van der Heijden DJ , WestendorpICD, RiezebosRKet al.: Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J. Am. Coll. Cardiol., 44, 20–24 (2004).
  • Mann T , CubedduRJ, RaynorLet al.: Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy. Cathet. Cardiovasc. Intervent., 58, 459–466 (2003).
  • Sabatine MS , CannonCP, GibsonCMet al.: CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med., 352, 1179–1189 (2005).
  • Sabatine MS , CannonCP, GibsonCMet al.: Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) – Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA, 294, 1224–1232 (2005).
  • Moliterno DJ , SteinhublSR: Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?JAMA, 294, 1271–1273 (2005).
  • Chen ZM , JiangLX, ChenYPet al.: COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 366, 1607–1621 (2005).
  • Smith SC et al. Jr, Feldman TE, Hirshfeld JW Jr : ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention – a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 47, 216–235 (2006).
  • Gurbel PA , BlidenKP, HiattBL, O’Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107, 2908–2913 (2003).
  • Gurbel PA , BlidenKP, HayesKM, YohoJA, HerzogWR, TantryUS: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.J. Am. Coll. Cardiol., 45, 1392–1396 (2005).
  • Barragan P , BouvierJL, RoquebertPOet al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv., 59, 295–302 (2003).
  • Lau WC , WaskellLA, WatkinsPBet al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation, 107, 32–37 (2003).
  • von Beckerath N , TaubertD, Pogatsa-MurrayGet al.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral doses for Immediate Clopidogrel Effect) trial. Circulation, 112, 2946–2950 (2005).
  • Taubert D , KastratiA, HarlfingerSet al.: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost., 92, 311–316 (2004).
  • Kastrati A , von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation, 110, 1916–1919 (2004).
  • Gurbel PA , BlidenKP, LauW, TantryUS: Clopidogrel resistance: implications for coronary stenting.Curr. Pharm. Des., 12(10), 1261–1269 (2006.
  • Willerson JT , YaoSK, McNattJet al.: Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc. Natl Acad. Sci. USA, 88, 10624–10628 (2006).
  • Morel O , HugelB, JeselLet al.: Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GP IIb-IIIa antagonists. J. Thromb. Haemost., 2, 1118–1126 (2004).
  • Schwarz M , NordtT, BodeC, PeterK: The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, αMβ2).Thromb Res., 107, 121–128 (2002).
  • Steiner S , SeidingerD, HuberKet al.: Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler. Thromb. Biol. Vasc., 23, 1697–1702 (2003).
  • Ibbotson T , McGavinJK, GoaKL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.Drugs, 63, 1121–1163 (2003).
  • Kondo K , UmemuraK: Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.Clin. Pharmacokinet., 41, 187–195 (2002).
  • Curran MP , KeatingGM: Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.Drugs, 65, 2009–2035 (2005).
  • Batchelor WB , TollesonTR, HuangYet al.: Randomized COMparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatide. Circulation, 106(12), 1470–1476 (2002).
  • Saucedo JF , GarzaL, WolfordDCet al.: Tennessee-Arkansas-Mississippi (TAM) Clinical Research Consortium. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am. J. Cardiol., 93, 1279–1282 (2004).
  • Topol EJ , MoliternoDJ, HerrmannHCet al.: TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med., 344, 1888–1894 (2001).
  • Saucedo JF , LuiHK, GarzaLet al.: Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. J. Thromb. Thrombol., 18, 67–74 (2004).
  • Simoons ML , GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet, 357, 1915–1924 (2001).
  • Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation, 96, 1445–1453 (1997).
  • EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med., 330, 956–961 (1994).
  • EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med., 336, 1689–1696 (1997).
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet, 349, 1429–1435 (1997).
  • Marso SP , LincoffAM, EllisSGet al.: Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation, 100, 2477–2484 (1999).
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet, 349, 1422–1428 (1997).
  • O’Shea JC , HafleyGE, GreenbergSet al.: ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA, 285, 2468–2473 (2001).
  • Boersma E , HarringtonRA, MoliternoDJet al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 359, 189–198 (2002).
  • Roffi M , ChewDP, MukherjeeDet al.: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation, 104, 2767–2771 (2001).
  • Montalescot G , BarraganP, WittenbergOet al.: ADMIRAL Investigators. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med., 344, 1895–1903 (2001).
  • Brener SJ , BarrLA, BurchenalJEet al.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation, 98, 734–741 (1998).
  • Tcheng JE , KandzariDE, GrinesCLet al.: CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation, 108, 1316–1323 (2003).
  • Montalescot G , BorentainM, PayotLet al.: Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA, 292, 362–366 (2004).
  • Kandzari DE , BergerPB, KastratiAet al.: and the ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J. Am. Coll. Cardiol., 44, 2133–2136 (2004).
  • Mehilli J , KastratiA, SchuhlenHet al.: Intracoronary Stenting and Antithrombotic Regimen: is abciximab a Superior Way to Eliminate Elevated Thrombotic risk in diabetics (ISAR-SWEET) study investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation, 110, 3627–3635 (2004).
  • Bhatt DL , MarsoSP, LincoffAMet al.: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll. Cardiol., 35, 922–928 (2000).
  • Pierce T , MarufRA, RazzukLM, Hoover SJ:A comprehensive review of physiology of hempstasis and antithrombotic agents. BUMC Proc., 12, 39–49 (1999).
  • Diener HC , CunhaL, ForbesC, SiveniusJ, SmetsP, LowenthalA: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.J. Neurol. Sci., 143, 1–13 (1996).
  • Jamieson DG , ParekhA, EzekowitzMD: Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.J. Cardiovasc. Pharmacol. Ther., 10, 153–161 (2005).
  • Weintraub WS : The vascular effects of cilastozol.Can. J. Cardiol., 22(Suppl. B), B56–B60 (2006).
  • Morishita R : A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.Atherosclerosis Suppl., 6(4), 41–46 (2005).
  • Thompson PD , ZimetR, ForbesWP, ZhangP: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.Am. J. Cardiol., 90, 1314–1319 (2002).
  • Maurer-Spurej E : Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection.Cell. Mol. Life Sci., 62, 159–170 (2005).
  • Hirsh J : Heparin.N. Engl. J. Med., 324, 1565–1574 (1991).
  • Xiao Z , TherouxP: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.Circulation, 97, 251–256 (1998).
  • Weitz JI , HudobaM, MasselD, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest., 86, 385–391 (1990).
  • Chong BH : Heparin-induced thrombocytopenia.J. Thromb. Haemost., 1, 1471–1478 (2003).
  • Oler A , WhooleyMA, OlerJ, GradyD: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.JAMA, 276, 811–815 (1996).
  • Hirsh J , WeitzJI: New antithrombotic agents.Lancet, 353, 1431–1436 (1999).
  • Antman EM , CohenM, RadleyDet al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation, 100, 1602–1608 (1999).
  • Mahaffey KW , FergusonJJ: Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.Am. Heart J., 149, S81–S90 (2005).
  • Montalescot G : STEEPLE: Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomised Evaluation. European Society of Cardiology hot line session. (2005) (Abstract 2578).
  • Eikelboom J , WhiteH, YusufS: The evolving role of direct thrombin inhibitors in acute coronary syndromes.J. Am. Coll. Cardiol., 41, S70–S78 (2003).
  • Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet, 359, 294–302 (2002).
  • Lincoff AM , BittlJA, HarringtonRAet al.: REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA, 289, 853–863 (2003).
  • Stone G : Prospective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition and Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes (ACUITY Trial). Presented at:The 55th Annual Scientific Session of American College of Cardiology. Atlanta, GA, USA, 11–14 March 2006.
  • Mateos-Careres PJ , Garcia-MendezAet al., Farre J : Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. Eur. J. Clin. Invest., 32, 895–900 (2002).
  • Osnes LT , FossKB, JooGBet al.: Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-κB/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor-α (TNF-α) in human monocytes. Thromb. Haemost., 76, 970–976 (1996).
  • Ferrari E , BenhamouM, CerboniP, Marcel B: Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J. Am. Coll. Cardiol., 45, 456–459 (2005).
  • Gaussem P , RenyJL, ThalamasCet al.: The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J. Thromb. Haemost., 3, 1437–1445 (2005).
  • Wallace JL , McKnightW, Del Soldato P, Baydoun AR, Cirino G: Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J. Clin. Invest., 96, 2711–2718 (1995).
  • Niitsu Y , JakubowskiJA, SugidachiA, Asai F: Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost., 31, 184–194 (2005).
  • Storey RF , OldroydKG, WilcoxRG: Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.Thromb. Haemost., 85, 401–407 (2001).
  • Husted S , EmanuelssonH, HeptinstallSet al.: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J., 27(9), 1038–1047 (2006).
  • Bavry AA , KumbhaniDJ, QuirozRet al.: Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am. J. Cardiol., 93, 830–835 (2004).
  • Kastrati A , MehilliJ, NeumannFJet al.: Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial. JAMA, 295(13), 1581–1582 (2006).
  • Beygui F , MontalescotG: The use of GP IIb/IIIa inhibitors into new perspectives:pre-catherization laboratory administration.Eur. Heart J., 7(Suppl. II), 110–114 (2005).
  • Ulrichts H , VanhoorelbekeKet al., Van De Walle G : New approaches for antithrombotic antiplatelet therapies. Curr. Med. Chem., 11, 2261–2263 (2004).
  • Gould WR , BaxiSM, SchroederRet al.: Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J. Thromb. Haemost., 3, 733–741 (2005).
  • Vishnevetsky D , KiyanistaVA, Gandhi PJ: CD40 ligand: a novel target in the fight against cardiovascular disease. Ann. Pharmacother., 38, 1500–1508 (2004).
  • Angelillo-Scherrer A , BurnierL, FloresNet al.: Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Invest., 115, 237–246 (2005).
  • Lutgens E , CleutjensKB, HeenemanSet al.: Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc. Natl Acad. Sci. USA, 97, 7464–7469 (2000).
  • Rossiello MR , MomiS, CaracchiniRet al.: A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J. Thromb. Haemost., 3, 2554–2562 (2005).
  • Inbal A , GurevitzO, TamarinIet al.: Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: in vitro and ex vivo inhibition of platelet function. Blood, 94, 1693–1700 (1999).
  • Popma JJ , BergerP, OhmanEMet al.: Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126, S576–S599 (2004).
  • Patrono C , BachmannF, BaigentCet al.: European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur. Heart J., 25, 166–181 (2004).
  • Boeynaems JM , van Giezen H, Savi P, Herbert JM: P2Y receptor antagonists in thrombosis. Curr. Opin. Investig. Drugs, 6(3), 275–282 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.